Navigation Links
PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies

BOSTON, July 24, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of  the PAREXEL BioPharm Unit -- a dedicated unit within PAREXEL focused solely on the unique needs of small and mid-sized biopharmaceutical companies to help them achieve their development goals.Recent data indicates[1] that small and mid-sized companies are the engine of the biopharmaceutical industry, with 81 percent of ongoing development programs originating from sponsors outside of the top 25 biopharmaceutical companies.  The PAREXEL BioPharm Unit seeks to support this critical pipeline by providing the precise expertise, global infrastructure, operational excellence and turn-key technologies needed to help small biopharmaceutical companies advance their drugs through the development cycle. Through vast experience and deep understanding of the needs of small and emerging biopharmaceutical companies, PAREXEL designed this new delivery model to provide a high level of attention and service. The goal is to provide a tailored solution that results in accelerated development timelines, reduced cost and a high level of quality.

"Small and mid-sized biopharmaceutical companies are truly the genesis of innovation and have been an important part of PAREXEL's client base for more than 30 years," said Ubavka DeNoble, Vice President of BioPharm Services. "The creation of the PAREXEL BioPharm Unit is especially important for small pharma and biotech sponsors that have needs that are meaningfully different from large pharma sponsors. The breadth and depth of our expertise gives us the ability to create customized solutions that are designed to meet the particular needs of each client -- whether the company is a small research venture, a growing mid-sized business, or a global enterprise."

The PAREXEL BioPharm Unit provides a senior management leader and dedicated team offering ongoing, frequent communication and proactive solutions. Under the dedicated team model, PAREXEL's BioPharm Unit provides companies the opportunity to accelerate patient recruitment, increase the speed of study start-up, shorten time to database lock, and improve overall efficiency for meeting critical development milestones.About PAREXEL InternationalPAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.


Contacts:Georgina Cattaway, Director of Marketing

Kim Leadley/Sarah Bruckner PAREXEL International

PAN CommunicationsTel: +44 1895 614530

Tel: + 617-502-4300Email:


SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
3. PAREXEL International To Present At NASDAQ OMX Investor Conference
4. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
5. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
6. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
9. Sanofi US Launches Collaborate Activate Innovation Challenge
10. Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
11. Ellman International Launches Multi-stage Growth Plan With Acquisition Of Sandstone Medical Technologies
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found with ... according to a study published online in the journal Radiology. Researchers said that ... necessitate a change in treatment. , Breast MRI is the most sensitive technique ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
Breaking Medicine News(10 mins):